GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (FRA:MB8) » Definitions » EV-to-FCF

Moberg Pharma AB (FRA:MB8) EV-to-FCF : -3.54 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Moberg Pharma AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Moberg Pharma AB's Enterprise Value is €36.22 Mil. Moberg Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-10.22 Mil. Therefore, Moberg Pharma AB's EV-to-FCF for today is -3.54.

The historical rank and industry rank for Moberg Pharma AB's EV-to-FCF or its related term are showing as below:

FRA:MB8' s EV-to-FCF Range Over the Past 10 Years
Min: -173.29   Med: -0.8   Max: 352.83
Current: -3.71

During the past 13 years, the highest EV-to-FCF of Moberg Pharma AB was 352.83. The lowest was -173.29. And the median was -0.80.

FRA:MB8's EV-to-FCF is ranked worse than
100% of 553 companies
in the Drug Manufacturers industry
Industry Median: 25.77 vs FRA:MB8: -3.71

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), Moberg Pharma AB's stock price is €1.289. Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.056. Therefore, Moberg Pharma AB's PE Ratio (TTM) for today is At Loss.


Moberg Pharma AB EV-to-FCF Historical Data

The historical data trend for Moberg Pharma AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB EV-to-FCF Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.68 -2.37 -2.97 -1.29 -2.35

Moberg Pharma AB Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -2.35 -4.32 -7.54 -1.41

Competitive Comparison of Moberg Pharma AB's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's EV-to-FCF falls into.



Moberg Pharma AB EV-to-FCF Calculation

Moberg Pharma AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=36.221/-10.223
=-3.54

Moberg Pharma AB's current Enterprise Value is €36.22 Mil.
Moberg Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (FRA:MB8) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Moberg Pharma AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.289/-0.056
=At Loss

Moberg Pharma AB's share price for today is €1.289.
Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.056.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Moberg Pharma AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

Moberg Pharma AB Headlines

No Headlines